A murine Zic3 transcript with a premature termination codon evades nonsense-mediated decay during axis formation Dis. Model. Mech., May 2013; 6: 755 - 767.
[ZIC5 ]
Brain and muscle Arnt-like 1 is a key regulator of myogenesis J. Cell Sci., May 2013; 126: 2213 - 2224.
[MyoD1]
CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer Cancer Res., May 2013; 73: 2795 - 2805.
[CHD1]
Deregulation of Wnt/ß-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors Carcinogenesis, May 2013; 34: 953 - 961.
[WIF1]
2 x 1 mL frozen cell vials each containing 1 x 10E6 cells
Mycoplasma:
Negative by DNA staining and direct culture methods (ATTC - detailed information available upon request)
Cell Line Validation:
Gene expression: qPCR experiments determined specific over-expression of SCN9A.Figure 1.
Functional validation
Current-Voltage relationship: activation The basic biophysical properties, expression levels, and pharmacology of Nav1.7-HEK293 cells were assessed using the IonWorks planar array electro-physiology platform. Figure 2, Figure 3
Expression stability Stable expression of hNav1.7 over multiple cell passages is confirmed. Figure 4, Figure 5
Pharmacology Inhibition of hNav1.7 Na+ currents by known Na+ channel blockers such as tetrodotoxin, ProTX-II, tetracaine and lidocaine. Figure 6
Background:
Human Nav1.7 (SCN9A) is a voltage-gated Na+ channel preferentially expressed in sensory neurones, which plays a key role in the depolarisation phase (upstroke) of the action potential. Mutations in this gene have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain, and paroxysmal extreme pain disorder. Nav1.7 is of interest as a target for novel analgesics.
Figure 1. qPCR data on specific over-expression of SCN9A. In a SYBR green qPCR experiment, specific over-expression of SCN9A was determined using gene specific primers. Data are shown as fold of over-expression after normalization against GAPDH.
Figure 2. Current-Voltage Relationship: Activation. A) Representative currents obtained by a family of depolarising pulses between -50 and +60 mV from a holding potential of -90 mV; B) Peak I-V relationship (mean ± SEM, n= 67); C) Normalised G (conductance) -V plot. To ensure appropriate voltage-clamp only cells with peak current amplitudes ranging from 0.4 to 1.2 nA were included. The threshold for activation was -30 mV and peak currents were obtained between 0 and +10 mV). The reversal potential was +60mV, close to the theoretical value of +66mV, calculated using the Nernst equation. From the G-V plot the Boltzmann parameters for activation were: V½ -7.5 mV, slope of 5.4 (mV/e-fold)
Figure 3. Current-Voltage Relationship: Inactivation. The voltage-dependence of inactivation was measured by applying long (1 s) conditioning pulses to varying potentials (-110 to -30 mV) followed by a test pulse to 0 mV. The Boltzmann parameters for inactivation were: V½ -60mV and slope 5.4(mV/e-fold). Currents are normalised to the current evoked by the test pulse following a conditioning potential of -110 mV. Data is presented as mean of 50 cells. SEM are too small to be clearly visible.
Figure 4. Expression Profile. At a step potential of 0mV, peak inward currents of >0.4 nA were observed in 324 of 370 cells (87%), with a mean amplitude of 2.02 ± 1.00 nA (n=324; mean ± S.D.). The maximum current evoked from a depolarising pulse to 0 mV was divided into 0.2 nA bins.
Figure 5. Expression Stability. Stable expression of hNav1.7 over multiple cell passages. The ordinate shows the mean (±SD) Na+ current amplitudes obtained from population patch clamp recordings from a Vh of -80mV. Note the stable expression for >35 passages.
Figure 6. Pharmacology. Inhibition of hNav1.7 Na+ currents by known Na+ channel blockers. The IC50 values are close to those previously described: tetrodotoxin (15nM), ProTX-II (4.1nM), tetracaine (6.5?M) and lidocaine (262?M). Currents were evoked by a 20 ms test pulse to 0mV from a holding potential of -90mV in the absence (control) and presence of inhibitor.
Figure 7. Cell Growth Properties. Images of cells at 60% confluency at low and high (inset) magnification. Growth curve (confluency) for HEK hNav1.7 cells seeded at 10% confluency at 37?C measured every 3 h for a total of 72 h.